The Nifty ended the month -3.40% (-4.30% in USD terms.)
Index Performance
IT was the only place to be long… everything else was just wrong.
Top Winners and losers
Well done HCL Tech, well done. Ranbaxy got tagged by the US FDA and JP Associates is the leading contender for one of the biggest break-downs this year.
ETFs
GOLDBEES | +1.77% |
NIFTYBEES | -3.18% |
INFRABEES | -4.53% |
JUNIORBEES | -6.81% |
BANKBEES | -9.68% |
PSUBNKBEES | -13.23% |
Brutal.
Advancers and Decliners
Yield Curve
Investment Theme Performance
Velocity* | +3.60% |
Balance-sheet Strength | +0.09% |
Financial Strength Value | -1.07% |
Momentum 200 | -1.13% |
Efficient Growth | -1.18% |
Consistent10* | -1.69% |
Market Elephants | -1.82% |
Enterprise Yield | -3.27% |
Magic Formula Investing | -3.62% |
Growth with Moat | -5.13% |
ADAG Mania | -5.60% |
Long Term Equity* | -5.85% |
Quality to Price | -8.83% |
Market Fliers | -13.90% |
Momentum carried the month.
Sector Performance
Thought to sum up the month
Well, we had too much to drink (infrastructure debt binge, etc.) before the GFC and spent the rest of the next 5 years barely recovering (NPAs, capital raises, etc.) from the hangover. But it looks like we are going to get trampled by the herd again.
Source: The levee breaks